Legal Representation
Attorney
Aaron D. Hendelman
USPTO Deadlines
Next Deadline
403 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-09-08)
Due Date
September 08, 2026
Grace Period Ends
March 08, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
13 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Feb 18, 2022 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Feb 18, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Feb 18, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Feb 18, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Feb 18, 2022 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Sep 8, 2020 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jun 23, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 23, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jun 3, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| May 19, 2020 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 12, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 27, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
| Feb 27, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Detailed Classifications
Class 042
Research and development in the pharmaceutical and biotechnology fields, namely, research and development for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; research and development for the use of antibody-oligonucleotide conjugates for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical and scientific research services for the use of antibody-oligonucleotide conjugates for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; development of pharmaceutical preparations and medicines, namely, the development of oligonucleotide-based therapeutics
First Use Anywhere:
20190100
First Use in Commerce:
20190100
Classification
International Classes
042